IL312392A - Neutralizing monoclonal antibodies against cervaviruses - Google Patents
Neutralizing monoclonal antibodies against cervavirusesInfo
- Publication number
- IL312392A IL312392A IL312392A IL31239224A IL312392A IL 312392 A IL312392 A IL 312392A IL 312392 A IL312392 A IL 312392A IL 31239224 A IL31239224 A IL 31239224A IL 312392 A IL312392 A IL 312392A
- Authority
- IL
- Israel
- Prior art keywords
- sarbecoviruses
- monoclonal antibodies
- antibodies against
- neutralizing monoclonal
- neutralizing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/102—Coronaviridae (F)
- C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21205626.1A EP4174083A1 (en) | 2021-10-29 | 2021-10-29 | Neutralizing monoclonal antibodies against sarbecoviruses |
| PCT/IB2022/056706 WO2023073441A1 (en) | 2021-10-29 | 2022-07-20 | Neutralizing monoclonal antibodies against sarbecoviruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL312392A true IL312392A (en) | 2024-06-01 |
Family
ID=78414544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL312392A IL312392A (en) | 2021-10-29 | 2022-07-20 | Neutralizing monoclonal antibodies against cervaviruses |
Country Status (6)
| Country | Link |
|---|---|
| EP (2) | EP4174083A1 (enExample) |
| JP (1) | JP2024540147A (enExample) |
| AU (1) | AU2022374853A1 (enExample) |
| CA (1) | CA3235310A1 (enExample) |
| IL (1) | IL312392A (enExample) |
| WO (1) | WO2023073441A1 (enExample) |
-
2021
- 2021-10-29 EP EP21205626.1A patent/EP4174083A1/en active Pending
-
2022
- 2022-07-20 IL IL312392A patent/IL312392A/en unknown
- 2022-07-20 JP JP2024525544A patent/JP2024540147A/ja active Pending
- 2022-07-20 EP EP22743926.2A patent/EP4423124A1/en active Pending
- 2022-07-20 AU AU2022374853A patent/AU2022374853A1/en active Pending
- 2022-07-20 CA CA3235310A patent/CA3235310A1/en active Pending
- 2022-07-20 WO PCT/IB2022/056706 patent/WO2023073441A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP4423124A1 (en) | 2024-09-04 |
| JP2024540147A (ja) | 2024-10-31 |
| CA3235310A1 (en) | 2023-05-04 |
| EP4174083A1 (en) | 2023-05-03 |
| WO2023073441A1 (en) | 2023-05-04 |
| AU2022374853A1 (en) | 2024-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE062777T2 (hu) | SARS-CoV-2 elleni antitestek | |
| EP4271707A4 (en) | NEUTRALISING MONOCLONAL ANTIBODIES AGAINST COVID-19 | |
| IL308741A (en) | Anti-SIRP-alpha antibodies | |
| ZA202205226B (en) | Ri-labeled humanized antibody | |
| PL4214240T3 (pl) | Przeciwciała anty-CCR8 | |
| GB202105110D0 (en) | Anti-CD73 antibodies | |
| GB202111905D0 (en) | Antibodies | |
| GB202305426D0 (en) | Antibodies | |
| GB202014851D0 (en) | SARS-COV-2 antibodies | |
| IL300142A (en) | Anti-IL13Ralpha2 antibodies | |
| GB202015115D0 (en) | ZIP12 Antibody | |
| GB201911211D0 (en) | Monoclonal antibodies against ambra-1 | |
| GB202105933D0 (en) | Anti-IL1rap antibody | |
| IL312392A (en) | Neutralizing monoclonal antibodies against cervaviruses | |
| IL308782A (en) | Antibodies | |
| IL308100A (en) | Antibodies | |
| GB202102227D0 (en) | Antibodies | |
| GB202008022D0 (en) | Antibodies | |
| GB202313544D0 (en) | monoclonal antibody | |
| GB202208773D0 (en) | Anti-SARS2-S antibodies | |
| GB202306125D0 (en) | Monoclonal antibody | |
| IL307175A (en) | IL-38 specific antibodies | |
| GB202116709D0 (en) | Antibodies | |
| GB202115824D0 (en) | Antibodies | |
| GB202112297D0 (en) | Antibodies |